These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36208441)

  • 1. Can tumor treating fields induce DNA damage and reduce cell motility in medulloblastoma cell lines?
    Nitta RT; Luo EJ; Lim M; Li G
    J Neurosurg Pediatr; 2022 Dec; 30(6):555-566. PubMed ID: 36208441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
    Nitta RT; Bolin S; Luo E; Solow-Codero DE; Samghabadi P; Purzner T; Aujla PS; Nwagbo G; Cho YJ; Li G
    Oncogene; 2019 Oct; 38(42):6867-6879. PubMed ID: 31406250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.
    Wenger C; Miranda PC; Salvador R; Thielscher A; Bomzon Z; Giladi M; Mrugala MM; Korshoej AR
    IEEE Rev Biomed Eng; 2018; 11():195-207. PubMed ID: 29993870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidine decreases the DNA damage and apoptosis caused by tumor-treating fields in cancer cell lines.
    Jeong H; Jo Y; Yoon M; Hong S
    Genes Genomics; 2021 Sep; 43(9):995-1001. PubMed ID: 33950471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
    Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo.
    Giladi M; Weinberg U; Schneiderman RS; Porat Y; Munster M; Voloshin T; Blatt R; Cahal S; Itzhaki A; Onn A; Kirson ED; Palti Y
    Semin Oncol; 2014 Oct; 41 Suppl 6():S35-41. PubMed ID: 25213867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields.
    Chang E; Pohling C; Beygui N; Patel CB; Rosenberg J; Ha DH; Gambhir SS
    J Neurooncol; 2017 Sep; 134(2):259-268. PubMed ID: 28681243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theory and application of TTFields in newly diagnosed glioblastoma.
    Yu A; Zeng J; Yu J; Cao S; Li A
    CNS Neurosci Ther; 2024 Mar; 30(3):e14563. PubMed ID: 38481068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice.
    Shi W; Blumenthal DT; Oberheim Bush NA; Kebir S; Lukas RV; Muragaki Y; Zhu JJ; Glas M
    J Neurooncol; 2020 Jul; 148(3):489-500. PubMed ID: 32535723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
    Mumblat H; Martinez-Conde A; Braten O; Munster M; Dor-On E; Schneiderman RS; Porat Y; Voloshin T; Davidi S; Blatt R; Shteingauz A; Tempel-Brami C; Zeevi E; Lajterer C; Shmueli Y; Danilov S; Haber A; Giladi M; Weinberg U; Kinzel A; Palti Y
    Lung Cancer; 2021 Oct; 160():99-110. PubMed ID: 34482104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma.
    Sarkari A; Korenfeld S; Deniz K; Ladner K; Wong P; Padmanabhan S; Vogel RI; Sherer LA; Courtemanche N; Steer C; Wainer-Katsir K; Lou E
    Elife; 2023 Nov; 12():. PubMed ID: 37955637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor treating fields: concept, evidence and future.
    Pless M; Weinberg U
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1099-106. PubMed ID: 21548832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Acting Dynamics.
    Voloshin T; Schneiderman RS; Volodin A; Shamir RR; Kaynan N; Zeevi E; Koren L; Klein-Goldberg A; Paz R; Giladi M; Bomzon Z; Weinberg U; Palti Y
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33080774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
    Voloshin T; Kaynan N; Davidi S; Porat Y; Shteingauz A; Schneiderman RS; Zeevi E; Munster M; Blat R; Tempel Brami C; Cahal S; Itzhaki A; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
    Cancer Immunol Immunother; 2020 Jul; 69(7):1191-1204. PubMed ID: 32144446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
    JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma.
    Riley MM; San P; Lok E; Swanson KD; Wong ET
    J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy.
    Karanam NK; Ding L; Aroumougame A; Story MD
    Transl Res; 2020 Mar; 217():33-46. PubMed ID: 31707040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor treating fields: a new frontier in cancer therapy.
    Davies AM; Weinberg U; Palti Y
    Ann N Y Acad Sci; 2013 Jul; 1291():86-95. PubMed ID: 23659608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
    Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
    Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.